# About Medicinal Ipamorelin: An Independent Editorial Dossier

> About Medicinal Ipamorelin — an independent editorial project publishing cited summaries of the ipamorelin research and regulatory record. Not a clinic, not a vendor.

Who publishes this site, what "medicinal" does and does not mean here, and the line we hold.

## What this site is

Medicinal Ipamorelin is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature and the regulatory record on ipamorelin. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the ipamorelin literature the way a newspaper's research desk would: lead with what was measured, attribute it to its source, and be candid about what the evidence does not show. Every quantitative claim on the site is tied to a numbered citation on the [Ipamorelin references](/references) page.

## What "medicinal" means here — and what it does not

The word "medicinal" in this domain name is editorial framing — a vantage point from which we examine ipamorelin's relationship to medicine and regulation. It is **not** a claim that ipamorelin is an approved medicine. It is not.

This distinction is the spine of the site. Ipamorelin has no approved human indication anywhere; its single published human trial failed its endpoint; and in 2024 it was removed from the FDA's 503A bulk-substances list. A domain modifier like "medicinal," "clinic," or "pharmaceutical" describes a position a publisher occupies relative to the literature, not a service the site offers or a status the compound holds. We are explicit about that throughout, and especially on the [is ipamorelin fda approved](/fda-approval) page.

## Our editorial standard

We work from primary sources — PubMed-indexed studies, clinical-trial records, and regulatory documents. We name the species and dose for every preclinical finding, so a reader never mistakes a rodent or ferret result for a human one. We do not publish dosing protocols, we do not recommend use, and we keep anecdotal community reports clearly separated from cited findings on the [Ipamorelin effects](/effects) page.

We describe ipamorelin generically, by its peptide name and structure, and avoid drug brand names entirely. Where the evidence is thin or negative — as it largely is for ipamorelin in humans — we say so plainly rather than dressing it up.

---

A broadsheet dossier on the ipamorelin record — the failed human trial, the 2024 compounding rollback, and the WADA prohibition reported in plain ink; no clinic behind the masthead and nothing here dosed, compounded, prescribed, or sold.